Founded in 2019 by a team of entrepreneurs and surgeons from Washington University in St. Louis, Caeli

Vascular Inc., has developed a Multi-Modal technology platform for the treatment of thrombotic obstructions along the entire continuum of disease. Our patented therapeutic bundle is designed to be both comprehensive and transformative and will establish a new paradigm for the treatment of multiple stages of thrombotic disease. 

​

40-55% of patients with Deep Vein Thrombosis (DVT) have large volume DVT that yields the poorest outcomes and places the patient at high risk of life-threatening Pulmonary Embolism (PE). Less than half of these patients receive endovascular care to remove the clot due to limitations with current technology.

 

Caeli Vascular's Thrombectomy System is designed specifically to safely and completely remove large volume DVT. Caeli's Multi-Modal technology will expand physicians' capability to target a wider range of disease, improve patient outcomes, and lower costs to healthcare institutions.